Goodpasture Syndrome Treatment Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2017 - 2025
- Transparency Market Research
Goodpasture syndrome is a rare autoimmune disease which affects both the kidneys and lungs. In this syndrome, antibodies are produced against a specific region of collagen in the lungs and kidneys. This syndrome includes conditions such as glomerulonephritis, i.e., inflammation of glomeruli, the presence of anti-GBM (glomerular basement membrane) antibodies, and bleeding in the lungs. This disease was first described by Ernest Goodpasture, in 1919. It is also known as anti-GBM disease. The disease can be fatal if not diagnosed and treated on time. Common symptoms of the disease include hemoptysis, dyspnea, cough, fatigue, hematuria, and fever.
The global Goodpasture syndrome treatment market is expected to expand at a steady pace during the forecast period. Goodpasture syndrome is a rare disease and according to the Clinical Kidney Journal the syndrome affects one to two persons per million in each year; however, seriousness of the disease is a key factor that is estimated to drive the market during the forecast period. Prevalence of unhealthy lifestyle such as smoking usage of tobacco, utilization of hair dyes, increase in geriatric population, steroid abuse, drug abuse, and exposure to hydrocarbons are a few major factors attributed to the expansion of the global market. Furthermore, promising pipeline, robust R&D, and rise in awareness in developed countries are also some factors that are anticipated to propel the global Goodpasture syndrome treatment market during the forecast period. Difficulties in diagnosis, low awareness in developing countries toward disease diagnosis and treatment, and strict regulation are a few key factors that are restraining the global Goodpasture syndrome treatment market.
The global Goodpasture syndrome treatment market can be segmented based on treatment type, end-user, and region. On the basis of treatment, the global Goodpasture syndrome treatment market can be divided into conventional treatment and pipeline drugs. The conventional treatment segment can be further sub-segmented into drugs which are used for the treatment of renal dysfunction such as immunosuppressive drugs, corticosteroid medication and plasmapheresis. The conventional treatment segment held a significant share of the market in 2016; however, it is expected to lose market share by the end of the forecast period due to strong pipeline product for the disease. In terms of end-user, the global Goodpasture syndrome treatment market can be classified into hospitals and clinics, home care, and others.
Based on region, the Goodpasture syndrome treatment market can be segregated into North America, Latin America, Europe, Asia Pacific, and Middle East & Africa. North America is anticipated to dominate the market, accounting for a prominent share of the global Goodpasture syndrome market during the forecast period. Increase in prevalence of unhealthy lifestyle, advanced technology, rise in awareness among people toward diagnosis of the disease, high healthcare expenditure, and increasing drug abuse are major factors fueling the North America Goodpasture syndrome treatment market. Europe is also anticipated to hold a significant share of the global market, followed by North America, in terms of revenue. The Asia Pacific market is anticipated to expand at a rapid pace during the forecast period due the increase in geriatric population, adoption of healthcare solutions for better standard of life, rise in awareness towards healthcare, and prevalence of unhealthy lifestyle. Countries such as Japan and Australia are presenting lucrative opportunities for the market due to awareness and rise in per capita healthcare expenditure in these countries.
Key players operating in the global Goodpasture syndrome treatment market are focusing on strategies such as acquisitions, mergers, investment in R & D, and establishing a strong pipeline in order to maintain a significant position in the market. Prominent players operating in the Goodpasture syndrome treatment market include Hansa Medical AB, Acer Therapeutics Inc., and Fibrostatin S.L.
The report offers a comprehensive evaluation of the market. It does so via in-depth qualitative insights, historical data, and verifiable projections about market size. The projections featured in the report have been derived using proven research methodologies and assumptions. By doing so, the research report serves as a repository of analysis and information for every facet of the market, including but not limited to: Regional markets, technology, types, and applications.
The study is a source of reliable data on:
- Market segments and sub-segments
- Market trends and dynamics
- Supply and demand
- Market size
- Current trends/opportunities/challenges
- Competitive landscape
- Technological breakthroughs
- Value chain and stakeholder analysis
The regional analysis covers:
- North America (U.S. and Canada)
- Latin America (Mexico, Brazil, Peru, Chile, and others)
- Western Europe (Germany, U.K., France, Spain, Italy, Nordic countries, Belgium, Netherlands, and Luxembourg)
- Eastern Europe (Poland and Russia)
- Asia Pacific (China, India, Japan, ASEAN, Australia, and New Zealand)
- Middle East and Africa (GCC, Southern Africa, and North Africa)
The report has been compiled through extensive primary research (through interviews, surveys, and observations of seasoned analysts) and secondary research (which entails reputable paid sources, trade journals, and industry body databases). The report also features a complete qualitative and quantitative assessment by analyzing data gathered from industry analysts and market participants across key points in the industry’s value chain.
A separate analysis of prevailing trends in the parent market, macro- and micro-economic indicators, and regulations and mandates is included under the purview of the study. By doing so, the report projects the attractiveness of each major segment over the forecast period.
Highlights of the report:
- A complete backdrop analysis, which includes an assessment of the parent market
- Important changes in market dynamics
- Market segmentation up to the second or third level
- Historical, current, and projected size of the market from the standpoint of both value and volume
- Reporting and evaluation of recent industry developments
- Market shares and strategies of key players
- Emerging niche segments and regional markets
- An objective assessment of the trajectory of the market
- Recommendations to companies for strengthening their foothold in the market
Note: Although care has been taken to maintain the highest levels of accuracy in TMR’s reports, recent market/vendor-specific changes may take time to reflect in the analysis.
Have query on this report?Make an Enquiry
More from Pharmaceutical
PharmaceuticalChinese Markets for Mental Illness Drugs
PharmaceuticalChinese Markets for Anti-Dermatomycosis Skin Drugs
PharmaceuticalChinese Markets for Incretion Drugs
PharmaceuticalChinese Markets for Hypertension Drugs
Pharmaceuticals and HealthcareGlobal Bionic Ears Market Professional Survey Report 2017
Pharmaceuticals and HealthcareNeuropsychiatric Disorder Cluster Drug Development Pipeline Review, 2017
Pharmaceuticals and HealthcareHepatitis Drug Development Pipeline Review, 2017